← Leaderboards
Ravit Boger
Johns Hopkins University
$5,491,372
Attributed
$5,491,372
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $763K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,491,372 · 10
By mechanism
R01$2,937,913 · 2
R21$852,282 · 2
R56$762,983 · 1
K08$540,168 · 1
R03$326,359 · 2
M01$71,667 · 2
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Maureen Renee Horton$5,996,995
- Deborah Persaud$30,632,571
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusInfectionCytomegalovirusReportingTransplant RecipientsAdultCytomegalovirus InfectionsViralAffectLaboratoriesPharmaceutical PreparationsImmunocompromised HostProteinsAcquired Immunodeficiency SyndromeMorbidity - Disease RateCongenital CytomegalovirusPathogenBaseImmunocompetentChildLeadFutureGenesCells
Grant awards (24)
Discovery and development of novel HCMV inhibitors$762,983
R56 · FY2025 · AI · contact PI
Autophagy activation â a novel strategy for inhibition of human cytomegalovirus$228,000
R21 · FY2023 · AI · contact PI
Autophagy activation â a novel strategy for inhibition of human cytomegalovirus$190,000
R21 · FY2022 · AI · contact PI
Contribution of Cytomegalovirus to Crohn's disease complications and recurrences$191,641
R21 · FY2019 · DK · contact PI
Contribution of Cytomegalovirus to Crohn's disease complications and recurrences$242,641
R21 · FY2018 · DK · contact PI
High Throughput Screening for Identification of Human Cytomegalovirus Inhibitors$205,481
R01 · FY2016 · DC · contact PI
High Throughput Screening for Identification of Human Cytomegalovirus Inhibitors$125,250
R01 · FY2016 · DC · contact PI
Novel Artemisinin Derivatives for Cytomegalovirus Therapy$410,000
R01 · FY2015 · AI · contact PI
High Throughput Screening for Identification of Human Cytomegalovirus Inhibitors$340,807
R01 · FY2015 · DC · contact PI
Novel Artemisinin Derivatives for Cytomegalovirus Therapy$410,000
R01 · FY2014 · AI · contact PI
High Throughput Screening for Identification of Human Cytomegalovirus Inhibitors$240,975
R01 · FY2014 · DC · contact PI
Novel Artemisinin Derivatives for Cytomegalovirus Therapy$385,400
R01 · FY2013 · AI · contact PI
Novel Artemisinin Derivatives for Cytomegalovirus Therapy$410,000
R01 · FY2012 · AI · contact PI
Novel Artemisinin Derivatives for Cytomegalovirus Therapy$410,000
R01 · FY2011 · AI · contact PI
MOLECULAR EPIDEMIOLOGY OF PRIMARY CMV INFECTION$136,113
K08 · FY2011 · AI · contact PI
MOLECULAR EPIDEMIOLOGY OF PRIMARY CMV INFECTION$135,237
K08 · FY2010 · AI · contact PI
CMV-encoded TNF receptor and viral dissemination$82,000
R03 · FY2010 · AI · contact PI
MOLECULAR EPIDEMIOLOGY OF PRIMARY CMV INFECTION$134,493
K08 · FY2009 · AI · contact PI
CMV-encoded TNF receptor and viral dissemination$82,000
R03 · FY2009 · AI · contact PI
MOLECULAR EPIDEMIOLOGY OF PRIMARY CMV INFECTION$134,325
K08 · FY2008 · AI · contact PI
Molecular Epidemiology of Primary CMV Infection$80,442
R03 · FY2008 · AI · contact PI
Molecular Epidemiology of Primary CMV Infection$81,917
R03 · FY2007 · AI · contact PI
CONGENITAL CYTOMEGALOVIRUS RESEARCH (SCREENING)$71,629
M01 · FY2007 · RR · contact PI
CONGENITAL CYTOMEGALOVIRUS RESEARCH$38
M01 · FY2007 · RR · contact PI